The Scientific Medical Effects of Ionizing Radiation Course, conducted once a year, focuses on the latest research about the medical effects of ionizing radiation to help clinicians, health physicists, and medical planners preserve troop health in the face of radiological/nuclear terrorism or warfare.

For additional information about AFRRI training opportunities, contact AFRRI Military Medical Operations at 301-295-1069 or press the "Request info about: MEIR courses" button on this web page. To view more AFRRI information products, go to this web page.

For questions or more information about the content of this presentation, contact the presentation author.
Radiation Injuries after the Chernobyl Accident: Management, Outcome, and Lessons Learned

Scientific Medical Effects of Ionizing Radiation (MEIR) Course
July 30, 2008

Alla Shapiro, M.D., PhD
Medical Officer,
US Food and Drug Administration
Center for Drug Evaluation and Research
Office of Counter-Terrorism and Emergency Coordination
I. What could have been done at Chernobyl to lessen the effects of radiation damage?

II. Health consequences

- Thyroid gland and radiation exposure
- Acute Radiation Syndrome (ARS) and its outcome
- Neuro-psychological impact
- Chernobyl experience of Cutaneous Radiation Syndrome (CRS)
- Other medical problems caused by the accident

III. Conclusions
What if....
Basic Information on the Radionuclide Releases and the Types of Exposure at Chernobyl

- 100% of gaseous fraction of the noble gases and nuclides may have escaped from the plant
- Cesium, Iodine and Tellurium isotopes accounted for up to 10-20% of the nuclides inventory
- Transuranic elements (Plutonium, Curium and Americium) were found only in the lungs
- Neutron irradiation was not significant
- ARS was caused by $\alpha$- and gamma-irradiation of the whole body and by beta-irradiation of the skin surface

Sheltering is an effective preventive action in the area within a radius of 3-10 km from the point of the accident even in the case of absence of confirming radiation measurements.

At Pripyat information about the need for sheltering was delayed.

For other populations including Kyiv, recommendations on sheltering were distributed on May 10, 1986 after the spread of radioiodine.

The efficiency of sheltering could not be assessed.
The preliminary decision to evacuate the town of Pripyat, which is located less than 3 km from the ChNPP, was taken on the afternoon of 26 April 1986, when the dose rate in some parts of the town reached several mSv/hour.

By 9 pm on 26 April 1986, 1,350 buses, 2 railway trains and 3 motor ships were brought into the Chernobyl district (12 km from the town of Pripyat).

At 10 pm the USSR Ministry of Public Health decided that the emergency evacuation of the town was necessary.
The organized evacuation of the town of Pripyat (49,360 including about 17,000 children and 80 bed-bound patients), was carried out on 27 April 1986, between 2 pm and 5 pm.
Iodine Prophylaxis

Official information from 1986

**Total:** It was administered to about 5 million people, including 1.6 million children

**Pripyat town:** It was administered to about 70% of the total population, including 60% on April 26

**Kiev Oblast:** Department of the Ministry of Health made a decision on iodine prophylaxis on May 6, **10 days** after the accident

**The Russian Federation:** It was administered to 71,930 people, including 25,060 children, **from June** to the middle of August 1986
Number of thyroid cancer cases in children and adolescents of Ukraine (aged 0-18 yrs) at the time of the Chernobyl accident

- **15-18**
- **0-14**
Distribution of thyroid cancer cases depending on patients’ age at the time of the accident

- 0 - 4
- 5 - 9
- 10 - 14
- 15 - 18

- 1986 - 1989
- 1990 - 1995
- 1996 - 2001
- 2002 - 2004
Papillary Carcinoma
Leukemia

• Consensus exists on the absence of leukemia excess in inhabitants of the contaminated territories (*French-German Initiative study*)

• There is a controversy in data on the leukemia incidence in children exposed *in utero*

Mutation *AML1* in ARS Survivors with Myelodisplastic Syndrome

During *AML1* gene sequenation in ARS survivor, who had suffered MDS, it was revealed punctuated mutation as repeating of 6 nucleotides

Patient No 24 / *AML1* wt

Patient No 263 / appel with ins 1502 (CGGCAT)

AK consecution with mutation
Conclusions

Studies in Ukraine have shown:

- an excess of thyroid cancer and non-cancer thyroid disease in children & other exposed groups (recovery operation workers, evacuees, adult population)

- a controversy in data on the leukemia incidence in children exposed in utero

- a dose-effect relationship on the leukemia incidence in recovery operation workers exposed to over 100 mSv
Conclusions (continued)

- an increase in the breast cancer incidence rate in females participating in recovery operation works in 1986/87 and female subpopulation still living in the most contaminated areas.

- an increase in all forms of cancer incidence rate only among recovery operation workers of 1986-1987 in comparison with national level.
Liquidators in Action
## Chernobyl, April 26, 1986: Sequence of the Initial Intervention

<table>
<thead>
<tr>
<th>Time</th>
<th>Intervention</th>
<th>Treatment/Disposition</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 min – 3-4 hours</td>
<td>Initial treatment on the site</td>
<td>• evacuation from the site, antiemetics, sedative, cardiotonic</td>
</tr>
</tbody>
</table>
| 4 hours - 12 hours | Evaluation and treatment at the nuclear plant medical facility | • discharged if condition is OK  
  • remained hospitalized |
| 12 hours - 36 hours | Specialized team arrived                              | • Assessment, blood tests, administration of KI, priority for hospitalization established |

Sequence of the Initial Intervention (continued)

- Within the first three days, **299 persons** were sent to the specialized treatment center in Moscow and to hospitals in Kiev.

- Over the subsequent days **hundreds** of additional persons were admitted for examination.

- Criteria for hospitalization included for patients with the suspected ARS:
  - Presence, time of onset and intensity of nausea and vomiting
  - Primary erythema of the skin
  - Decrease of the lymphocyte count in the peripheral blood <1X10⁹/L in first 24 hours after the exposure

**Thousands of concerned citizens were admitted to the hospitals for examination and blood work.**
### Primary Diagnostic Criteria of ARS: Diagnostic Coefficient (DC)

Assessment of irreversible myelosuppression according to DC in cases of ARS

<table>
<thead>
<tr>
<th>Time to the onset of vomiting</th>
<th>Hours</th>
<th>Diagnostic Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-0.4</td>
<td>+8</td>
</tr>
<tr>
<td></td>
<td>0.41-0.8</td>
<td>+4</td>
</tr>
<tr>
<td></td>
<td>0.81-1.2</td>
<td>+2</td>
</tr>
<tr>
<td></td>
<td>1.21-1.6</td>
<td>-2</td>
</tr>
<tr>
<td></td>
<td>&gt;2.0</td>
<td>-10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymphocyte count</th>
<th>$10^9 x 1-1$</th>
<th>Diagnostic Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocyte count on Day 2</td>
<td>0-0.2</td>
<td>+6</td>
</tr>
<tr>
<td>Lymphocyte count on Day 2</td>
<td>0.61-0.8</td>
<td>-15</td>
</tr>
<tr>
<td>Lymphocyte count Days 4 – 7</td>
<td>0.01</td>
<td>+5</td>
</tr>
<tr>
<td>Lymphocyte count Days 4 – 7</td>
<td>&gt;0.15</td>
<td>-15</td>
</tr>
</tbody>
</table>

A sum of **+10** is the basis for the prognosis of irreversible myelosuppression; a sum of **-10** is a prognosis for NO irreversible myelosuppression.
# The Severity and Outcome of ARS in Chernobyl Victims

<table>
<thead>
<tr>
<th>ARS Grade</th>
<th>Dose (Gy)</th>
<th>Number of Patients</th>
<th>Total</th>
<th>Alive</th>
<th>Died</th>
<th>(days to death)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>0.8 - 2.1</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>II</td>
<td>2.0 - 4.0</td>
<td>43</td>
<td>42</td>
<td>42</td>
<td>1</td>
<td>96</td>
</tr>
<tr>
<td>III</td>
<td>4.2 - 6.3</td>
<td>21</td>
<td>14</td>
<td>14</td>
<td>7</td>
<td>16 - 48</td>
</tr>
<tr>
<td>IV</td>
<td>6.0 - 16.0</td>
<td>20</td>
<td>1</td>
<td>1</td>
<td>19</td>
<td>14 - 91</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>115</td>
<td>88</td>
<td>88</td>
<td>27</td>
<td></td>
</tr>
</tbody>
</table>

The Bone Marrow Syndrome and its Treatment in Chernobyl Victims (1)

- **Antiseptic regimen**
  - Isolation
  - Air sterilization
  - Changes of underclothing for patients at least once/day
  - Maintaining the micro-organism population at less than 500/mm³ in the room air

- **Supportive therapy**
  - Antimicrobial decontamination of the intestine
  - Administration of systemic antibiotics
  - Acyclovir
  - Transfusions of blood cells (e.g. fresh donor platelets and RBC)

Supportive Therapy for Neutropenia

- Oral quinolones, fluconazole, acyclovir prophylactically
- Standard care for hemopoietic failure
- All blood products irradiated at 25 Gy
- Other supportive measures ad libitum
The New Concept of the ARS

- 1 Gy
  - Subclinical
  - Reversible if heterogenous irradiation

- 4 Gy
  - Bone Marrow (SOF)

- 6-8 Gy
  - MODS

- 30 Gy
  - Neurovascular (SOF)

- 50 Gy
  - MOF

Increasing dose
Bone Marrow Syndrome and its Treatment in Chernobyl Victims (2)

• HLA-matched unrelated bone marrow donors from large HLA-typed volunteer donor pools – 13 patients

• Fetal liver cells – 6 patients

• Bone marrow syndrome combined with other Injuries
  • Skin
  • GI
  • Oropharyngeal
  • Radiation pneumonitis
<table>
<thead>
<tr>
<th>Number of patients died (TOTAL = 27)</th>
<th>Days of death after the exposure</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>14 - 34</td>
<td>In 20/22 patients β-burns were the main cause of death</td>
</tr>
<tr>
<td>5</td>
<td>48 – 99*</td>
<td>Died after the bone marrow recovery stage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>* Patient on Day #96 died from ischemic stroke</td>
</tr>
</tbody>
</table>

Indications for an Allogenic BMT or an Embryonic Live Cell Transplantation

- Whole body γ-irradiation dose 6.0 Gy - 16.0 Gy
- Irreversible degree of myelosuppression using a Diagnostic Coefficient (DC) plus additional criteria
  - Vomiting during the first 30 minutes
  - Diarrhea during 1-2 hours after the exposure
  - Swelling of the parotid glands during the first 24-36 hours

Ref: UNSCEAR 1988 Report
### Outcome (Survival or Cause of Death) in Patients Receiving BMT

<table>
<thead>
<tr>
<th>Dose range (Gy)</th>
<th>Bone marrow transplant patients</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of patients</td>
<td>Deaths*</td>
<td>Deaths**</td>
<td>Number of survivors</td>
</tr>
<tr>
<td>&lt; 6.5</td>
<td>4</td>
<td>0</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>6.5 – 9.0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>&gt; 9.0</td>
<td>6</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL</td>
<td>13</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

*skin and GI injuries  
**GVHD + infection

Hemopoetic Stem Cell Transplants ???

- Never an emergency!
- Not if MODS!
- Always consider heterogeneity of irradiation and possibility of autologous hemopoietic recovery
- HLA typing immediate
- Transplant never before day 14-21
- Low immunosuppression: fludarabine ± ATG
- High cell dose $2 \times 10^6$ CD34/kg (peripheral blood), $2 \times 10^8$ nucleated cells/kg (bone marrow) and $3 \times 10^7$ nucleated cells (cord blood)
Problems that Complicated the Use of BMT for Chernobyl Victims

- Determination of the radiation dose
- Several kinds of irradiation (external γ- and β, and inhaled and ingested isotopes)
- Partial shielding of body parts by physical structures
- Rapid onset of lymphocytopenia made HLA typing difficult. Donor-recipient histocompatibility was not accurately determined
- Most individuals who received a sufficiently high dose of irradiation had thermal burns as well as injuries to the GI tract and other tissues
## Causes of Death among ARS Survivors (1986 through 2006)

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Grade I ARS</th>
<th>Grade II ARS</th>
<th>Grade III ARS</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncological and oncohematological pathology</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Sudden cardiac death</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Internal organ systems and neurological diseases</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Traumas and accidents</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>6</strong></td>
<td><strong>7</strong></td>
<td><strong>5</strong></td>
<td><strong>18</strong></td>
</tr>
</tbody>
</table>
# Oncological Diseases in ARS Survivors and non-ARS Patients

<table>
<thead>
<tr>
<th>No</th>
<th>Group</th>
<th>Diagnosis</th>
<th>First revealed</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>non-ARS</td>
<td>Sarcoma of hip soft tissues</td>
<td>1992</td>
<td>Died in 1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cancer of colon</td>
<td>1999</td>
<td>Operated in 1999</td>
</tr>
<tr>
<td>3</td>
<td>non-ARS</td>
<td>Cancer of colon</td>
<td>2001</td>
<td>Died in 2005</td>
</tr>
<tr>
<td>4</td>
<td>non-ARS</td>
<td>Cancer of kidney</td>
<td>2000</td>
<td>Operated in 2001</td>
</tr>
<tr>
<td>5</td>
<td>non-ARS</td>
<td>Cancer of stomach</td>
<td>2004</td>
<td>Died in 2004</td>
</tr>
<tr>
<td>6</td>
<td>non-ARS</td>
<td>Cancer of stomach</td>
<td>2004</td>
<td>Died in 2005</td>
</tr>
<tr>
<td>7</td>
<td>non-ARS</td>
<td>Cancer of lung</td>
<td>2001</td>
<td>Operated in 2003</td>
</tr>
<tr>
<td>8</td>
<td>non-ARS</td>
<td>Cancer of prostate</td>
<td>2001</td>
<td>Died in 2003</td>
</tr>
<tr>
<td>9</td>
<td>non-ARS</td>
<td>Cancer of throat</td>
<td>2000</td>
<td>Died in 2001</td>
</tr>
<tr>
<td>10</td>
<td>ARS 1 d.</td>
<td>Cancer of colon</td>
<td>1997</td>
<td>Operated in 1997</td>
</tr>
<tr>
<td>12</td>
<td>ARS 2 d.</td>
<td>Cancer of thyroid gland</td>
<td>2000</td>
<td>Operated in 2001</td>
</tr>
<tr>
<td>13</td>
<td>ARS 2 d.</td>
<td>Neurinoma of lower jaw</td>
<td>2003</td>
<td>Died in 2004</td>
</tr>
</tbody>
</table>
Non-bone Marrow Syndromes Caused by Radiation Exposure

<table>
<thead>
<tr>
<th>Acute Radiation Syndrome</th>
<th>Skin burns (%)</th>
<th>Oropharyngeal Syndrome (%)</th>
<th>Gastro-intestinal (%)</th>
<th>Radiation Pneumonitis (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>115</td>
<td>56 (48.6)</td>
<td>80 (69.5)</td>
<td>17 (14.7)</td>
<td>7 (6.1)</td>
</tr>
</tbody>
</table>

Barabanova A., Vojnosanit Pregl. 2006 May;63(5):477-80
Ministry of Health, Clinical Department of the Institute of Biophysics, Moscow, Russia. abarabanova@rambler.ru
# Stages of CRS

<table>
<thead>
<tr>
<th>Stage</th>
<th>Onset</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prodromal</td>
<td>24-72 hours</td>
<td>Transient erythema, pruritis</td>
</tr>
<tr>
<td>Manifestation</td>
<td>Days – 4 weeks</td>
<td>Intense erythema, edema, pruritis, pain, blisters, erosions, ulcerative necrosis</td>
</tr>
<tr>
<td>Subacute</td>
<td>4-6 weeks</td>
<td>Erythema, edema, ulcers</td>
</tr>
<tr>
<td>Chronic</td>
<td>3 months-2 years</td>
<td>Keratosis, fibrosis, ulcer, atrophy, pigment alteration, subcutaneous vasculitis, ulceration</td>
</tr>
<tr>
<td>Late</td>
<td>Decades</td>
<td>Ulcers, angioma, fibrosis, keratosis, basal cell carcinoma</td>
</tr>
</tbody>
</table>

*Stages of the CRS according to Second Consensus Development Conference on the Management of Radiation Injuries, Bethesda, MD, 1993*
<table>
<thead>
<tr>
<th>ARS (Grade)</th>
<th>Number of patients</th>
<th>Body area</th>
<th>Early skin lesions (1986)</th>
<th>Late skin lesions</th>
<th>Basal Cell Carcinoma (BCC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>5</td>
<td>feet, LE, trunk, hands</td>
<td>Erythema, edema</td>
<td>Atrophy, pigment alteration, xerosis</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>6</td>
<td>LE, UE, trunk + LE</td>
<td>Erythema, edema</td>
<td>Atrophy, pigment alteration, xerosis, keratosis, ulcers</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>9</td>
<td>Combinations of the above</td>
<td>Erythema, edema, blisters, ulcers</td>
<td>Atrophy, pigment alteration, fibrosis keratosis, ulcers</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>1</td>
<td>trunk + extremities</td>
<td>Blisters, ulcers</td>
<td>Same as Grade III plus carcinomas</td>
<td>2 BCC lesions</td>
</tr>
<tr>
<td>Non-confirmed group</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Patient N. In 1986 suffered from severe ARS (3rd degree) and moderate-severe acute skin damage (2nd - 3rd degree) of right foot. Essential keratosis and fibrosis. Nail bone of 1 finger was amputated in 1986, the focus with transplanted skin are well visible.

*Courtesy of Drs Belyi and Bebeshko, Kiev, Ukraine*
Chronic Cutaneous Radiation Syndrome (CRS)

Patient K. In 1986 suffered from severe ARS (3rd degree) and severe acute radiation skin damage of both shins (3rd degree). On the frontal surface foci of hyperpigmentation and telangiectasis are visible (15 years had passed)

*Courtesy of Drs Belyi and Bebeshko, Kiev, Ukraine*
Chronic Cutaneous Radiation Syndrome (CRS)

Patient N. In 1986 suffered from severe ARS (3rd degree) and moderate acute skin damage (2nd degree) of right leg. After 15 years following skin changes dominate: telangiectasis, hyperpigmentation, keratosis, fibrosis. 

*Courtesy of Drs Belyi and Bebeshko, Kiev, Ukraine*
Treatment Experience of Skin Injuries in Chernobyl victims

• Systemic treatment
  Hemoperfusion, plasmapheresis, continuous
  heparinization and administration of freshly frozen
  plasma

• Local treatment
  Use of Combutec-2 for local treatment of skin injuries
  Aerosol Lioxanol
  Solution Balis-2

• Pain management
  was challenging and not effective due to an
  absence of the local anesthetics in the treatment arsenal

• Necessity of surgical operations at an early stage
Non-radiological Health Effects

- Psychological effects
  - Can overwhelm radiological physical effects
  - Symptoms are similar for different radiation emergencies (different scales)
  - Need for comprehensive strategy directed to different population groups before/during/after an emergency
“The largest public health problem unleashed by the accident is the mental health impact”

(WHO report of the UN Chernobyl expert group, August 2005)

- Stress-related symptoms
- Chronic Fatigue Syndrome
- Effects on the developing brain
- Organic brain disorders in highly exposed clean-up workers
- Suicide
Brain Damage in Clean-up Workers

“Today it is recognized that the Central Nervous System (CNS) is a radiosensitive organ whose degree of dysfunction can be quantified by electrophysiological, biochemical and/or behavior parameters. Abnormalities in CNS function defined by these parameters may occur at a low dose of whole body radiation”
1. Children irradiated *in utero* in the first 4-5 months of gestation have:
   - reduced verbal IQ at age 11
   - ECG changes in the left hemisphere

2. Treatment with low dose radiation in infancy leads neuropsychological disorders later in life
Schizophrenia Incidence Excess in Chernobyl Exclusion Zone Personnel

Neuro-Psychological Consequences: Summary

• Genetic predisposition to schizophrenia can be provoked by environmental stressors including effects of exposure to ionizing radiation

• Left hemisphere is the most radiovulnerable

• Neuroimaging abnormalities are revealed following exposure to >0.3 Sv

• The CNS effects that could be attributed to exposure to ionizing radiation are as follows: schizophrenia spectrum disorders; Chronic Fatigue Syndrome; accelerated aging processes and neurodegeneration; and suicide
The risk of development of cerebrovascular diseases is higher in recovery operation workers with doses of 0.25 Gy and higher as compared to those with an exposure of less than 0.1 Gy.

![Graph showing the risk of cerebrovascular diseases over years with different dose ranges.]
Lessons Learned: Twenty years of Follow-up after the Chernobyl Accident (1)

• Cutaneous component of the ARS had significantly complicated the clinical prognosis and contributed to or caused death in patients

• Severe beta-burns of the skin remain an unsolved problem as a result of their spreading

• The severity of the skin damage could have been avoided by removing the contaminated clothing

• The prevention of late skin effects depends upon the effective management of acute lesions
Lessons Learned: Twenty years of Follow-up after the Chernobyl Accident (2)

• Communications: who/how to contact, how to verify and confirm information

• Confidentiality: different understanding of what was classified and what was not, limited information available for International professional community

• Public health implications of the radiological accident: International significance was not as well understood as for communicable diseases incidents
Lessons Learned: Twenty years of Follow-up after the Chernobyl Accident (3)

• The outcomes and late effects of the skin lesions depended on the depth-dose distribution and on the size of the area affected

• Radiation-induced fibrosis is a predominant clinical problem

• Appearance of secondary ulcerations presents treatment challenges

• No malignant melanoma or squamous cell carcinoma have been detected so far
"An accident has occurred at Chernobyl nuclear power station. One of the atomic reactors has been damaged. Measures are being taken to eliminate the consequences of the accident. Aid is being given to the victims. A government commission has been set up."
Be clear of what you are trying to say!
Lessons Learned: Twenty years of Follow-up after the Chernobyl Accident (4)

- Effective medical care is generally **not possible** for accident victims with high-dose TBI

- Most individuals will not receive a sufficiently high dose to make a bone marrow transplant necessary for hematological recovery

- Only a small number of patients will have bone marrow syndrome **without** other life-threatening non-bone marrow related complication

- Transplants should probably be considered for victims receiving more than **7 to 8 Gy** of external radiation
Lessons Learned: Twenty years of Follow-up after the Chernobyl Accident (5)

• Maximize the education of physicians

• Provide medical community with practical tools how to identify and assess radiation victims

• Explain situation in plain language and avoid conflicting information

• Stay in touch with collaborating centers in European and other countries experienced in managing radiation emergencies
Invisible danger still exists
What was the most unexpected for us?

• Diversity of clinical manifestations of skin lesions

• Unaccustomed course of clinical phases of a radiation injury to skin

• Significant severity of injuries

• Serious influence of skin burns on the general state of a patient

• Need for surgical interventions at an early stage
LUCK FAVORS THE PREPARED!

Thank You!
Acknowledgements:

- M. Tronko, T. Bogdanova et al, G. Thomas et al, Institute of Endocrinology and Metabolism, Acad. Med. Sc., Ukraine; Swansea University, UK; University, Japan; Institute of Oncology and Radiology, Acad. Med. Sc., Ukraine


- Ihor J. Masnyk, Ph.D., NCI, Epidemiology Branch U.S. Director Chornobyl Research Projects

- M. N.

- Savkin, L. A. Ilyin, A. K. Guskova

- State Research Center – Institute of Biophysics, Moscow, Russia

- Albert L. Wiley, MD, PhD, Director, Radiation Emergency Assistance Center Training Site (REAC/TS)

- Patrick Gourmelon, T. M. Fliedner and V. Meineke, Institute for Radiation and Nuclear Safety (France), University of ULM (Germany)

- Pierre Flor-Henry, Konstantin Loganovsky, Alberta Hospital Edmonton, Canada, Research Centre for Radiation Medicine, AMS of Ukraine, Kyiv
Radioprotectants Currently Approved in Russian Federation

ANTI-RADIATION FIRST- AID KIT CREATED

Includes:

- **INDRALIN** – neutralizes Cesium and Strontium
- **LIOXAZOL (spray)** – for early treatment of radiation sickness and spray for skin burns
- **ZASHITA (PROTECTION)** – deactivation and protection of skin
Radioprotectants approved in Russian Federation (continued)

- **DEZOXYNATUM** stimulates the proliferation of hemopoietic cells
- **Chemical structure:** Sodium salt of DNA extracted from the milt of sturgeon species
- **Mechanism of Action:** stimulates proliferation of hemopoietic cells
- **Indication:** ARS, hypo- and aplastic anemia secondary to chemo or radiation therapy
- **Contraindications:** none
- **Side effects:** low grade fever (infrequent)